je.st
news
Tag: meeting
Meeting Notes March 19, 2015
2015-04-20 19:42:27| PortlandOnline
Word Document, 44kbCategory: ESC/PAC Meeting Notes
Tags: march
notes
meeting
march meeting
MRI Interventions to Exhibit Its ClearPoint Navigation Platform for Neurosurgery at AANS 2015 Annual Meeting
2015-04-20 12:31:14| Industrial Newsroom - All News for Today
IRVINE, Calif. MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint neuro navigation platform will be on exhibit at the 2015 Annual Meeting of the American Association of Neurological Surgeons (AANS) May 4-6, 2015, in Washington, D.C. Conference attendees are invited to visit the MRI...
Tags: navigation
meeting
annual
platform
Early Findings with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
2015-04-19 18:45:00| Merck.com - Product News
Dateline City: PHILADELPHIA KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Mercks Innovative Basket Trial in 20 Cancers PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 28 percent with KEYTRUDA in patients with tumors that expressed PD-L1. Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
early
presented
meeting
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in nave and previously-treated patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
advanced
journal
published
April 9, 2015 -- Meeting Agenda
2015-04-17 22:53:52| PortlandOnline
PDF Document, 208kbCategory: Meeting Agendas
Sites : [639] [640] [641] [642] [643] [644] [645] [646] [647] [648] [649] [650] [651] [652] [653] [654] [655] [656] [657] [658] next »